Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v)

8 febbraio 2021 aggiornato da: Novartis Pharmaceuticals

A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Screening/Subject eligibility: Subjects with histologically confirmed cutaneous melanoma that was either unresectable or metastatic (Stages IIIC or IV), were screened for eligibility. Eligible subjects were BRAF V600E or V600K mutation positive. Subjects who had prior systemic anti-cancer treatment in the advanced or metastatic setting were not eligible although prior systemic treatment in the adjuvant setting was allowed.

Randomization: A total of 704 subjects were randomized in a ratio of 1:1 to receive combination therapy (352 subjects) or vemurafenib treatment (352 subjects). Subjects were stratified by LDH level (> the ULN versus =< ULN) and BRAF mutation (V600E versus V600K).

Study treatment: Dabrafenib and trametinib were administered orally at their recommended doses of 150 mg b.i.d. and 2.0 mg once daily, respectively. Subjects randomized in the combination therapy arm received both the agents. Subjects randomized in the vemurafenib arm received vemurafenib at the recommended dose of 960 mg orally b.i.d. Subjects in both the arms continued treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent. The protocol was amended on 07-Aug-2014 which allowed subjects who were still receiving vemurafenib to cross over to the dabrafenib and trametinib combination arm, including those subjects who were still receiving vemurafenib monotherapy treatment after disease progression. A washout period of a minimum of 7 days was considered prior to initiating dabrafenib in combination with trametinib. Subjects who experienced disease progression on the vemurafenib monotherapy arm, discontinued vemurafenib monotherapy, and subsequently received another anticancer therapy were ineligible for cross over to the dabrafenib and trametinib combination arm.

Follow-up/Study closure: After study treatment discontinuation, subjects were followed for survival and disease progression as applicable. This study completed once all the subjects had at least the 5-years of follow-up.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

704

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Argentina
      • Ciudad Autonoma de Buenos Aires, Argentina, C1121ABE
        • Novartis Investigative Site
      • San Miguel de Tucuman, Argentina, T4000IAK
        • Novartis Investigative Site
      • Santa Fe, Argentina, 3000
        • Novartis Investigative Site
    • Buenos Aires
      • Capital Federal, Buenos Aires, Argentina, C1426ANZ
        • Novartis Investigative Site
    • Río Negro
      • Viedma, Río Negro, Argentina, R8500ACE
        • Novartis Investigative Site
    • Santa Fe
      • Rosario, Santa Fe, Argentina, S2000KZE
        • Novartis Investigative Site
  • Australia
    • New South Wales
      • North Sydney, New South Wales, Australia, 2060
        • Novartis Investigative Site
      • Westmead, New South Wales, Australia, 2145
        • Novartis Investigative Site
    • Queensland
      • Greenslopes, Queensland, Australia, 4120
        • Novartis Investigative Site
      • Herston, Queensland, Australia, 4029
        • Novartis Investigative Site
      • South Brisbane, Queensland, Australia, 4101
        • Novartis Investigative Site
    • South Australia
      • Woodville, South Australia, Australia, 5011
        • Novartis Investigative Site
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Novartis Investigative Site
      • Melbourne, Victoria, Australia, 3004
        • Novartis Investigative Site
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Novartis Investigative Site
  • Austria
      • Graz, Austria, A-8036
        • Novartis Investigative Site
      • Innsbruck, Austria, 6020
        • Novartis Investigative Site
      • Salzburg, Austria, A-5020
        • Novartis Investigative Site
      • Wien, Austria, 1090
        • Novartis Investigative Site
      • Wien, Austria, A-1030
        • Novartis Investigative Site
  • Belgio
      • Brasschaat, Belgio, 2930
        • Novartis Investigative Site
      • Brussel, Belgio, 1090
        • Novartis Investigative Site
      • Brussels, Belgio, 1200
        • Novartis Investigative Site
      • Gent, Belgio, 9000
        • Novartis Investigative Site
      • Kortrijk, Belgio, 8500
        • Novartis Investigative Site
      • Leuven, Belgio, 3000
        • Novartis Investigative Site
      • Namur, Belgio, 5000
        • Novartis Investigative Site
      • Wilrijk, Belgio, 2610
        • Novartis Investigative Site
  • Brasile
      • Sao Paulo - SP, Brasile, 01323-900
        • Novartis Investigative Site
    • Rio Grande Do Sul
      • Ijui, Rio Grande Do Sul, Brasile, 98700-000
        • Novartis Investigative Site
    • Santa Catarina
      • Itajai, Santa Catarina, Brasile, 88301-215
        • Novartis Investigative Site
  • Canada
      • Quebec, Canada, G1R 2J6
        • Novartis Investigative Site
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N2
        • Novartis Investigative Site
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 5L3
        • Novartis Investigative Site
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Novartis Investigative Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Novartis Investigative Site
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Novartis Investigative Site
    • Ontario
      • Kingston, Ontario, Canada, K7L 5P9
        • Novartis Investigative Site
      • Oshawa, Ontario, Canada, L1G 2B9
        • Novartis Investigative Site
      • Ottawa, Ontario, Canada, K1H 8L6
        • Novartis Investigative Site
      • Toronto, Ontario, Canada, M5G 2M9
        • Novartis Investigative Site
      • Toronto, Ontario, Canada, M4N 3M5
        • Novartis Investigative Site
    • Quebec
      • Montreal, Quebec, Canada, H2L 4M1
        • Novartis Investigative Site
  • Cechia
      • Olomouc, Cechia, 775 20
        • Novartis Investigative Site
      • Ostrava, Cechia, 708 52
        • Novartis Investigative Site
      • Praha 10, Cechia, 100 34
        • Novartis Investigative Site
      • Praha 2, Cechia, 128 08
        • Novartis Investigative Site
      • Zlin, Cechia, 76275
        • Novartis Investigative Site
  • Corea, Repubblica di
      • Goyang-si, Gyeonggi-Do, Corea, Repubblica di, 410-769
        • Novartis Investigative Site
      • Seoul, Corea, Repubblica di, 03080
        • Novartis Investigative Site
      • Seoul, Corea, Repubblica di, 135-710
        • Novartis Investigative Site
  • Danimarca
      • Arhus C, Danimarca, 8000
        • Novartis Investigative Site
      • Herlev, Danimarca, 2730
        • Novartis Investigative Site
      • Odense, Danimarca, 5000 C
        • Novartis Investigative Site
  • Federazione Russa
      • Chelyabinsk, Federazione Russa, 454087
        • Novartis Investigative Site
      • Magnitogorsk, Federazione Russa, 455001
        • Novartis Investigative Site
      • Moscow, Federazione Russa, 115478
        • Novartis Investigative Site
      • Moscow, Federazione Russa, 143423
        • Novartis Investigative Site
      • Nizhniy Novgorod, Federazione Russa, 603081
        • Novartis Investigative Site
      • Ryazan, Federazione Russa, 390011
        • Novartis Investigative Site
      • St. Petersburg, Federazione Russa, 197758
        • Novartis Investigative Site
  • Finlandia
      • Helsinki, Finlandia, 00029
        • Novartis Investigative Site
      • Jyvaskyla, Finlandia, 40620
        • Novartis Investigative Site
      • Tampere, Finlandia, 33520
        • Novartis Investigative Site
      • Turku, Finlandia, 20520
        • Novartis Investigative Site
  • Francia
      • Bordeaux, Francia, 33075
        • Novartis Investigative Site
      • Grenoble, Francia, 38043
        • Novartis Investigative Site
      • Lille, Francia, 59037
        • Novartis Investigative Site
      • Marseille cedex 5, Francia, 13385
        • Novartis Investigative Site
      • Montpellier cedex 5, Francia, 34295
        • Novartis Investigative Site
      • Nantes, Francia, 44093
        • Novartis Investigative Site
      • Nice, Francia, 06202
        • Novartis Investigative Site
      • Paris Cedex 10, Francia, 75475
        • Novartis Investigative Site
      • Reims Cedex, Francia, 51092
        • Novartis Investigative Site
      • Rennes Cedex, Francia, 35042
        • Novartis Investigative Site
      • Villejuif cedex, Francia, 94805
        • Novartis Investigative Site
  • Germania
    • Baden-Wuerttemberg
      • Heidelberg, Baden-Wuerttemberg, Germania, 69120
        • Novartis Investigative Site
      • Heilbronn, Baden-Wuerttemberg, Germania, 74078
        • Novartis Investigative Site
      • Mannheim, Baden-Wuerttemberg, Germania, 68167
        • Novartis Investigative Site
      • Tuebingen, Baden-Wuerttemberg, Germania, 72076
        • Novartis Investigative Site
    • Bayern
      • Erlangen, Bayern, Germania, 91054
        • Novartis Investigative Site
      • Muenchen, Bayern, Germania, 80337
        • Novartis Investigative Site
      • Muenchen, Bayern, Germania, 80804
        • Novartis Investigative Site
      • Muenchen, Bayern, Germania, 80802
        • Novartis Investigative Site
      • Nuernberg, Bayern, Germania, 90419
        • Novartis Investigative Site
      • Regensburg, Bayern, Germania, 93053
        • Novartis Investigative Site
      • Wuerzburg, Bayern, Germania, 97080
        • Novartis Investigative Site
    • Niedersachsen
      • Buxtehude, Niedersachsen, Germania, 21614
        • Novartis Investigative Site
      • Hannover, Niedersachsen, Germania, 30625
        • Novartis Investigative Site
    • Nordrhein-Westfalen
      • Bonn, Nordrhein-Westfalen, Germania, 53127
        • Novartis Investigative Site
      • Essen, Nordrhein-Westfalen, Germania, 45122
        • Novartis Investigative Site
      • Koeln, Nordrhein-Westfalen, Germania, 50937
        • Novartis Investigative Site
    • Rheinland-Pfalz
      • Ludwigshafen, Rheinland-Pfalz, Germania, 67063
        • Novartis Investigative Site
      • Mainz, Rheinland-Pfalz, Germania, 55131
        • Novartis Investigative Site
    • Sachsen
      • Dresden, Sachsen, Germania, 01307
        • Novartis Investigative Site
      • Leipzig, Sachsen, Germania, 04103
        • Novartis Investigative Site
    • Sachsen-Anhalt
      • Magdeburg, Sachsen-Anhalt, Germania, 39120
        • Novartis Investigative Site
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Germania, 24105
        • Novartis Investigative Site
      • Luebeck, Schleswig-Holstein, Germania, 23538
        • Novartis Investigative Site
    • Thueringen
      • Erfurt, Thueringen, Germania, 99089
        • Novartis Investigative Site
      • Gera, Thueringen, Germania, 07548
        • Novartis Investigative Site
  • Irlanda
      • Co.Cork, Irlanda
        • Novartis Investigative Site
      • Dublin, Irlanda, 7
        • Novartis Investigative Site
      • Dublin, Irlanda, 9
        • Novartis Investigative Site
      • Dublin, Irlanda, 4
        • Novartis Investigative Site
      • Galway, Irlanda
        • Novartis Investigative Site
  • Israele
      • Jerusalem, Israele
        • Novartis Investigative Site
      • Ramat Gan, Israele, 52621
        • Novartis Investigative Site
  • Italia
    • Campania
      • Napoli, Campania, Italia, 80131
        • Novartis Investigative Site
    • Lazio
      • Roma, Lazio, Italia, 00167
        • Novartis Investigative Site
    • Liguria
      • Genova, Liguria, Italia, 16132
        • Novartis Investigative Site
    • Lombardia
      • Bergamo, Lombardia, Italia, 24128
        • Novartis Investigative Site
      • Milano, Lombardia, Italia, 20133
        • Novartis Investigative Site
      • Milano, Lombardia, Italia, 20141
        • Novartis Investigative Site
    • Toscana
      • Pisa, Toscana, Italia, 56126
        • Novartis Investigative Site
    • Veneto
      • Padova, Veneto, Italia, 35128
        • Novartis Investigative Site
  • Norvegia
      • Kristiansand, Norvegia, 4604
        • Novartis Investigative Site
      • Lorenskog, Norvegia, 1478
        • Novartis Investigative Site
      • Oslo, Norvegia, 0310
        • Novartis Investigative Site
  • Nuova Zelanda
      • Christchurch, Nuova Zelanda, 8011
        • Novartis Investigative Site
      • Newtown, Wellington, Nuova Zelanda, 6002
        • Novartis Investigative Site
  • Olanda
      • Amsterdam, Olanda, 1066 CX
        • Novartis Investigative Site
      • Amsterdam, Olanda, 1081 HV
        • Novartis Investigative Site
      • Groningen, Olanda, 9713 GZ
        • Novartis Investigative Site
      • Leeuwarden, Olanda, 8934 AD
        • Novartis Investigative Site
      • Leiden, Olanda, 2333 ZA
        • Novartis Investigative Site
      • Rotterdam, Olanda, 3015 GD
        • Novartis Investigative Site
  • Polonia
      • Gdansk, Polonia, 80-215
        • Novartis Investigative Site
      • Konin, Polonia, 62-500
        • Novartis Investigative Site
      • Poznan, Polonia, 60-693
        • Novartis Investigative Site
      • Warszawa, Polonia, 02-781
        • Novartis Investigative Site
  • Regno Unito
      • Cambridge, Regno Unito, CB2 0QQ
        • Novartis Investigative Site
      • Glasgow, Regno Unito, G12 0YN
        • Novartis Investigative Site
      • London, Regno Unito, NW3 2QG
        • Novartis Investigative Site
      • London, Regno Unito, SE1 7EH
        • Novartis Investigative Site
      • Manchester, Regno Unito, M20 4BX
        • Novartis Investigative Site
      • Southampton, Regno Unito, SO16 6YD
        • Novartis Investigative Site
      • Swansea, Regno Unito, SA2 8QA
        • Novartis Investigative Site
  • Spagna
      • Barcelona, Spagna, 08036
        • Novartis Investigative Site
      • Hospitalet de Llobregat, Barcelona, Spagna, 08907
        • Novartis Investigative Site
      • Las Palmas De Gran Canaria, Spagna, 35016
        • Novartis Investigative Site
      • Madrid, Spagna, 28007
        • Novartis Investigative Site
      • Madrid, Spagna, 28050
        • Novartis Investigative Site
      • Palma de Mallorca, Spagna, 07010
        • Novartis Investigative Site
      • Pamplona, Spagna, 31008
        • Novartis Investigative Site
      • Valencia, Spagna, 46014
        • Novartis Investigative Site
      • Valencia, Spagna, 46009
        • Novartis Investigative Site
  • Stati Uniti
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35243
        • Novartis Investigative Site
    • Arizona
      • Gilbert, Arizona, Stati Uniti, 85234
        • Novartis Investigative Site
    • California
      • Beverly Hills, California, Stati Uniti, 90211
        • Novartis Investigative Site
      • San Francisco, California, Stati Uniti, 94115
        • Novartis Investigative Site
      • Vallejo, California, Stati Uniti, 94589
        • Novartis Investigative Site
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80010
        • Novartis Investigative Site
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32204
        • Novartis Investigative Site
      • Miami Beach, Florida, Stati Uniti, 33140
        • Novartis Investigative Site
      • Orlando, Florida, Stati Uniti, 32804
        • Novartis Investigative Site
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Novartis Investigative Site
      • Atlanta, Georgia, Stati Uniti, 30341
        • Novartis Investigative Site
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • Novartis Investigative Site
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Novartis Investigative Site
    • Minnesota
      • Fridley, Minnesota, Stati Uniti, 55432
        • Novartis Investigative Site
    • Missouri
      • Saint Louis, Missouri, Stati Uniti, 63110
        • Novartis Investigative Site
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89148
        • Novartis Investigative Site
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Novartis Investigative Site
      • New Brunswick, New Jersey, Stati Uniti, 08901
        • Novartis Investigative Site
    • New York
      • New York, New York, Stati Uniti, 10029
        • Novartis Investigative Site
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599-7600
        • Novartis Investigative Site
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Novartis Investigative Site
      • Durham, North Carolina, Stati Uniti, 27710
        • Novartis Investigative Site
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45219
        • Novartis Investigative Site
      • Columbus, Ohio, Stati Uniti, 43210
        • Novartis Investigative Site
    • Oregon
      • Bend, Oregon, Stati Uniti, 97701
        • Novartis Investigative Site
      • Portland, Oregon, Stati Uniti, 97213
        • Novartis Investigative Site
      • Portland, Oregon, Stati Uniti, 97239
        • Novartis Investigative Site
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29425
        • Novartis Investigative Site
      • Greenville, South Carolina, Stati Uniti, 29605
        • Novartis Investigative Site
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Novartis Investigative Site
    • Texas
      • Dallas, Texas, Stati Uniti, 75246
        • Novartis Investigative Site
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84106
        • Novartis Investigative Site
      • Salt Lake City, Utah, Stati Uniti, 84112-5550
        • Novartis Investigative Site
    • Vermont
      • Burlington, Vermont, Stati Uniti, 05403
        • Novartis Investigative Site
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22903
        • Novartis Investigative Site
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Novartis Investigative Site
  • Svezia
      • Linkoping, Svezia, SE-581 85
        • Novartis Investigative Site
      • Umea, Svezia, SE-901 85
        • Novartis Investigative Site
  • Svizzera
      • Basel, Svizzera, 4031
        • Novartis Investigative Site
      • Lausanne, Svizzera, 1011
        • Novartis Investigative Site
      • Zurich, Svizzera, 8091
        • Novartis Investigative Site
  • Taiwan
      • Tainan, Taiwan, 704
        • Novartis Investigative Site
      • Taipei, Taiwan, 100
        • Novartis Investigative Site
      • Taoyuan, Taiwan, 333
        • Novartis Investigative Site
  • Ucraina
      • Dnipropetrovsk, Ucraina, 49102
        • Novartis Investigative Site
      • Donetsk, Ucraina, 83092
        • Novartis Investigative Site
      • Kharkiv, Ucraina, 61070
        • Novartis Investigative Site
      • Kyiv, Ucraina, 03022
        • Novartis Investigative Site
      • Lviv, Ucraina, 79031
        • Novartis Investigative Site
      • Sumy, Ucraina, 40005
        • Novartis Investigative Site
      • Uzhgorod, Ucraina, 88017
        • Novartis Investigative Site
  • Ungheria
      • Budapest, Ungheria, H-1122
        • Novartis Investigative Site
      • Budapest, Ungheria, 1062
        • Novartis Investigative Site
      • Debrecen, Ungheria, 4032
        • Novartis Investigative Site
      • Gyor, Ungheria, H-9024
        • Novartis Investigative Site
      • Kaposvar, Ungheria, 7400
        • Novartis Investigative Site
      • Miskolc, Ungheria, 3526
        • Novartis Investigative Site
      • Szeged, Ungheria, 6720
        • Novartis Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key Inclusion Criteria:

  • >= 18 years of age
  • Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma
  • Measurable disease according to RECIST 1.1
  • Women of childbearing potential with negative serum pregnancy test prior to randomisation
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Adequate baseline organ function

Key Exclusion Criteria:

  • Any prior use of a BRAF or MEK inhibitor
  • Prior systemic anti-cancer treatment in the advanced or metastatic setting; prior systemic treatment in the adjuvant setting is allowed
  • History of another malignancy (except subjects who have been disease free for 3 years or with a history of completely resected non-melanoma skin cancer)
  • Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)
  • Brain metastases (except if all known lesions were previously treated with surgery or stereotactic radiosurgery and lesions, if still present, are confirmed stable for >= 12 weeks prior to randomisation or if no longer present are confirmed no evidence of disease for >= 12 weeks, and are asymptomatic with no corticosteroid requirements for >= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for >= 4 weeks prior to randomisation
  • History or evidence of cardiovascular risk (LVEF < LLN; QTcB >= 480 msec; blood pressure or systolic >=140 mmHg or diastolic >= 90 mmHg which cannot be controlled by anti-hypertensive therapy)
  • History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dabrafenib plus Trametinib
BRAF inhibitor plus MEK inhibitor
Droga: Dabrafenib
Dabrafenib 150 mg twice daily orally
Altri nomi:
  • GSK2118436
Droga: Trametinib
Trametinib 2 mg once daily orally
Altri nomi:
  • GSK1120212
Comparatore attivo: Vemurafenib
BRAF inhibitor
Droga: Vemurafenib
Vemurafenib 960 mg twice daily orally
Altri nomi:
  • Monoterapia

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Survival (OS)
Lasso di tempo: From the date of randomization until date of death due to any cause (up to approximately 6 years)
Overall Survival (OS) was defined as the interval of time between the date of randomization and the date of death due to any cause. For patients who did not die, OS was censored at the date of last contact.
From the date of randomization until date of death due to any cause (up to approximately 6 years)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-Free Survival (PFS), as Assessed by the Investigator
Lasso di tempo: From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)
Progression-free survival (PFS) was defined as the interval of time between the date of randomization and the first documented occurrence of disease progression or death due to any cause. PFS for investigator-assessed response was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression was defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)
Overall Response Rate (ORR) During Randomized Phase, as Assessed by the Investigator
Lasso di tempo: From randomization until the first documented complete response or partial response (up to approximately 6 years)
Overall response was defined as the percentage of confirmed responders (complete response [CR] + partial response [PR] per RECIST, Version 1.1) as summarized by Investigator assessment. CR was defined as the disappearance of all evidence of target lesions. PR was defined as at least a 30% reduction from Baseline in the sum of the longest diameter (LD) of all target lesions. Data were reported as those participants with measureable disease at Baseline.
From randomization until the first documented complete response or partial response (up to approximately 6 years)
Duration of Response (DOR), as Assessed by the Investigator
Lasso di tempo: From the time of the first documented response (CR or PR) until disease progression (up to approximately 6 years)
Duration of Response (DOR) was defined as the time from the first documented evidence of a CR (disappearance of all evidence of target lesions) or a PR (at least a 30% reduction from Baseline in the sum of the longest diameter of all target lesions) until disease progression or death due to any cause. PD was defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of at least1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Data were summarized per RECIST, Version 1.1.
From the time of the first documented response (CR or PR) until disease progression (up to approximately 6 years)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Novartis Pharmaceuticals

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 giugno 2012

Completamento primario (Effettivo)

17 aprile 2014

Completamento dello studio (Effettivo)

25 aprile 2019

Date di iscrizione allo studio

Primo inviato

10 maggio 2012

Primo inviato che soddisfa i criteri di controllo qualità

10 maggio 2012

Primo Inserito (Stima)

14 maggio 2012

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 febbraio 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 febbraio 2021

Ultimo verificato

1 febbraio 2021

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 116513
  • CDRB436B2302 (Altro identificatore: Novartis)
  • 2011-006088-23 (Numero EudraCT)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Sì

Descrizione del piano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Dabrafenib

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in India

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi